Managing early breast cancer

References

• Jemal A, Tiwari RC, Murray T, et al; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54(1): 8–29
   Google Scholar
• Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Oncol 1989; 5(2): 102–10
   Google Scholar
• McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326(26): 1756–61
   PubMed Web of Science ®Google Scholar
• Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: a reproducibility study. Cancer 1994; 73(11): 2765–70
   Google Scholar
• De Vita VT Jr, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2001: 1651–88
   Google Scholar
• Paik S, Shak S, Tang G, et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients—NSABP studies B-20 and B-14. Presented at the 26th Annual San Antonio Breast Cancer Symposium, Dec 4, 2003, San Antonio, Tex
   Google Scholar
• Cobleigh MA, Bitterman P, Baker J, et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughput RT-PCR assay of paraffin-embedded tumor tissues. Presented at the 39th American Society of Clinical Oncology Annual Meeting, Jun 2003, Chicago
   Google Scholar
• Esteban J, Baker J, Cronin M-L, et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. Presented at the 39th American Society of Clinical Oncology Annual Meeting, Jun 2003, Chicago
   Google Scholar
• Benda RK, Mendenhall NP, Lind DS, et al. Breast-conserving therapy (BCT) for early-stage breast cancer. J Surg Oncol 2004; 85(1): 14–27
   Google Scholar
• Kern KA. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999; 189(6): 539–45
   Google Scholar
• Rubio IT, Korourian S, Cowan C, et al. Sentinel lymph node biopsy for staging breast cancer. Am J Surg 1998; 176(6): 532–7
   Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21 (17): 3357–65
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16): 1233–41
   PubMed Web of Science ®Google Scholar
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352(9132): 930–42
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8(9): 1483–96
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21(6): 976–83
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21 (8): 1431–9 [Erratum, J Clin Oncol 2003; 21(11): 2226]
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar A, Cuzick J, et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98(9): 1802–10
   PubMed Web of Science ®Google Scholar
• Abraham J, Allegra C, eds. Bethesda handbook of clinical oncology. Philadelphia: Lippincott, Williams & Wilkins, 2001: 127–41
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349(19): 1793–802
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350(11): 1081–92
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Presented at the San Antonio Breast Cancer Symposium, Dec 3, 2003, San Antonio, Tex. Available at http://www.abstracts2view.com/bcs03/view.php?nu=BCS3L_338. Accessed Aug 18, 2004
   Google Scholar
• Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001; (30): 67–71
   Google Scholar